

Sustainability Phase: PCV13 Vaccination for Elderly Patients aged ≥65 years on Follow Up with TTSH Integrative Family Physician Clinic



Adj A/Prof Wong Teck Yee

Department of Continuing & Community Care (CCC)


Mission Statement


To increase the monthly percentage of elderly patients aged 65 years and above on follow-up with TTSH Integrative Family Physician Clinic who had been vaccinated with PCV13 (Pneumococcal Conjugate Vaccine 13-Valent) from 24% to 70% over a sustained period


Team Members					
	Name	Designation	Department		
Team Leader	Adj A/Prof Wong Teck Yee	Family Physician, Senior Consultant	CCC		
Team	Ms Zhang Jin (till 9/2019)	Nurse Clinician	CCC		
Members	Ms Liu Yu (till 5/2020)	Senior Staff Nurse	CCC		
	Ms Zhou Hui Ling	Senior Staff Nurse	CCC		
	Ms Avril Ho (till 9/2019 & since 5/2020)	Executive	Operations (DICC)		
	Mr Tan Zong Rui (10/2019-5/2020)	Executive	Operations (Community Health)		
Sponsor	Adj Asst Prof Tan Kok Leong	Head of Department & Senior Consultant	CCC		
Mentor	Adj A/Prof Julie George				

Evidence for a Problem Worth Solving

- 1. Vaccination coverage in USA: National Health Interview Survey, 2018: Pneumococcal vaccination among adults ≥ 65 years old = 68.9%
- 2. Low monthly percentage of IFPC elderly patients aged \geq 65 years old vaccinated with PCV 13 = 22 26% (Jan-Apr 2019)








Pareto Chart Factors leading to low monthly percentage of Variable practices in IFPC Elderly Patients Vaccinated with PCV13 Cause 1 vaccination counselling 100.0 100 93.3 Variable practices in Cause 2 offering PCV13 of Vote Lack of patient knowledge Cause 3 Numper 4 40 PCV13 perceived as costly Cause 4 Lack of education Cause 5 materials Cause 1 Cause 2 Cause 3 Cause 4 Cause 5

Implementation				
Root Cause	Intervention	Implementation Date		
Cause A: Variable practices in vaccination counselling	PDSA 1A: New workflow to include PCV13 counselling by nurses prior to doctor's consultation	1 st Week Jul 2019		
	PDSA 1B: Create PCV13 kit (Vaccine Information Sheet & brochures in various languages & PCV13 Cost Illustration Card)	3 rd Week Jul 2019		
	PDSA 1C: Use of Pneumococcal Vaccination Checklist in C-Doc	1 st Week Aug 2019		
Cause B : Variable practices in offering PCV13	PDSA 2: Offer vaccination 1 more time at next review visit	1 st Week Nov 2019		

Results

Sustainability Phase: % of IFPC Patients ≥ 65yrs old Vaccinated with PCV13



Since Year 2021, the interventions have been incorporated as part of the TTSH Integrative Family Physician Clinic (IFPC) daily workflow.

Compliance to all interventions was ensured with regular briefings and roll calls.

Random audit will be done to ensure compliance to interventions. PDSA cycles will kick in to make refinement to the existing intervention when necessary.

Cost Savings					
Class A Ward Accommodation	Estimated Total Bill for Standard Case (\$)	Estimated Total Bill for Complex Case (\$)			
Geriatric Medicine 14 days admission	9,029	24,419			
Respiratory & Critical Care Medicine 7 days admission	5,939	23,325			
General Medicine 5 days admission	6,098	24,091			
Cost of PVC13 (\$)	9	8			
Potential cost savings to patient per admission prevented	\$5,841 to \$8,931	\$23,227 to \$24,321			

Problems Encountered

- 1. Challenging to advocate PCV13 as it is not as commonly known and more costly (cf. influenza vaccination) → more effort needed for patient acceptance
- 2. Patients generally opt not to have more than 1 vaccination at the same time → prefer influenza vaccination over PCV13 when they are due for influenza vaccinations → PCV13 postponed to subsequent visits

Strategies to Sustain

- 1. Regular tracking of quality indicator
- 2. Monthly updates on the progress of the project to the team and engaging team members for discussions on continuous improvement & sustaining performance